Alteplase in COVID-19 severe hypoxemic respiratory failure: the TRISTARDS multicenter randomized trial

Giovanni Landoni,Pratima Chowdary,Ferhat Meziani,Jacques Creteur,Nicolas De Schryver,Johann Motsch,Ingrid Henrichmoeller,Alain Pagès,Nuala Peter,Thierry Danays,Markus A. Weigand,the TRISTARDS Investigators,Alexander Zoufaly,Tamara Seitz,Erich Pawelka,Stephanie Neuhold,Wolfgang Höpler,Benedikt Rumpf,David Totschnig,Rudolf Likar,Markus Koestenverger,Stefan Neuwersch-Sommeregger,Jacques Creteur,Amedee Ego,Anthony Moreau,David Grimaldi,Filippo Annoni,Julie Gorham,Katarina Halenarova,Zoe Pletschette,Alexandre Brasseur,Fabio Taccone,Leda Nobile,Olivier Lheureux,Morgane Snacken,Charles Dehout,Nicolas De Schryver,Marco Vinetti,Nicolas Serck,Thierry Dugernier,Nathalie Layios,Gilles Parzibut,Rodrigo Boldo,Vanessa Santos dos Santos,Cristine Erdmann Nunes,Jean-Luc Diehl,N Aissaoui,J Augy,E Guerot,C Hauw-Berlemont,B Hermann,N Peron,F Santi,J Langlais,A Troger,K Chekhrit,Julien Poissy,M Caplan,A El Kalioubie,R Favory,A Gaudet,J Goutay,S Preau,A Rouze,Laure Mariller,Jean-Paul Mira,Z Ait Hamou,S Ben Ghanem,M Bertrix,J Charpentier,T Creutin,M Jozwiak,D Laghlam,E Peju,F Pene,C Vigneron,Ferhat Meziani,J Demisselle,J Helms,L Jandeaux,C Kummerlen,H Merdji,A Monnier,H Rahmani,A Studer,S Cunat,Ouafa Hakkari,Xavier Monnet,I Adda,N Anguel,S Ayed,Q Fosse,L Guerin,D Osman,A Pavot,T Pham,C Carpentier,P Denormandie,C Lai,Alain Fourreau,Mehran Monchi,O Ellrodt,S Jochmans,S Mazerand,N Rolin,J Serbource-Goguel,P Soulier,O Sy,Nourdine Benane,Bruno Mourvillier,J Cousson,A Goury,O Passouant,G Thery,Cédric Castex,Jean-Baptiste Lascarrou,A Roquilly,E Canet,C Garret,J Lemarie,M Martin,J Reignier,A Seguin,O Zambon,P Lamouche Wilquin,M Agbakou,P Decamps,L Desmedt,G Blonz,Y Hourmant,N Grillot,A Rouhani,M Bouras,P.-J. Mahe,D. Demeure Dit Latte,A Bourdiol,N Benkalfate,M Carpentier,F Guillotin,S Benguerfi,Johann Motsch,Johannes Zimmermann,Karam Al Halabi,Marc Altvater,Sebastian Decker,Mascha Fiedler,Phillip Knebel,Barbara Maichle,Markus Weigand,Tobias Welte,Nora Drick,Isabelle Pink,Julius Johannes Schmidt,Sven Bercker,Philipp Simon,Falk Fichtner,Gunther Hempel,Peter Kliem,Karsten Kluba,Sven Laudi,Sarah Müller,Rene Oesemann,Michael Roedel,Stefan Schering,Sebastian Schulz,Christian Seeber,Hannah Ullmann,Svitlana Ziganshyna,Nora Jahn,Bastian Boerge,Maren Keller,Michael Irlbeck,Sandra Frank,Ursula Hoffmann,Aydin Huseynov,Simone Britsch,Gill Ishar-Singh,Claude Jabbour,Sven Stieglitz,Jan-Erik Guelker,Maurizio Cecconi,Massimiliano Greco,Giacomo Monti,Maria Luisa Azzolini,Beatrice Righetti,Francisco Marquez Diaz,Sofía Elizabeth Girón,Alejandra Aviles de La Cruz,Ana Elena Ramírez Ibarra,Paola Hernández Romo,Marián Serna García,Andrés García Castillo,Peter Spronk,Marnix Kuindersma,Michiel Blans,Henk Leeuwen,Marco Peters,Els Rengers,Oscar Hoiting,Viktor Borisovich Filimonov,Maria Peshenniokva,Olga Kravchenko,Yuri Karev,Anastasiia Filimonova,Sergey Nikolaevich Avdeev,Svetlana Chikina,Tatiana Gneusheva,Zamira Merzhoeva,Galina Nekludova,Denis Nikolaevich Protsenko,Igor Tyurin,Nikita Matyushkov,Tatiana Valerievna V. Lisun,Aleksandr Boyarkov,Svetlana Bobkova,Alexey Klinov,Dmitry Schukarev,Nikolay Smolin,Ricard Ferrer,Xavier Nuvials,Sofia Contreras,Alejandro Cortés,Mariel Rojas Lora,Rafael Sierra,Samer Alarbe,Ana Fernandez,Mario Contreras,María Dolores Freire,Jaume Revuelto,Mikel Celaya,Judith Marín,Francisco Parrilla,Purificación Perez,Rosana Muñoz,Emilio Diaz,Cristina Mora,Candelaria de Haro,Edgard Moglia
DOI: https://doi.org/10.1186/s13613-024-01386-z
IF: 10.318
2024-11-13
Annals of Intensive Care
Abstract:Pulmonary intravascular thrombus formation has been widely observed in patients with respiratory failure, for example, in patients with SARS-CoV-2 infection (COVID-19). The aim of this study was to evaluate the efficacy/safety of alteplase thrombolysis in COVID-19 severe hypoxemic respiratory failure. In this multicenter, open-label study, patients were randomized to receive alteplase (low- or high-dose) over 5 days plus standard of care (SOC), or SOC alone. The primary endpoint was time to clinical improvement (≥ 2-point decrease on WHO Clinical Progression Scale, or hospital discharge) up to Day 28. Secondary endpoints included all-cause mortality at Day 28, treatment failure at Day 28 and change in arterial oxygen partial pressure/fractional inspired oxygen (PaO 2 /FiO 2 ) ratio at Day 6 versus baseline.
critical care medicine
What problem does this paper attempt to address?